|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: YAF2 |
Gene summary for YAF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | YAF2 | Gene ID | 10138 |
| Gene name | YY1 associated factor 2 | |
| Gene Alias | YAF2 | |
| Cytomap | 12q12 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8IY57 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10138 | YAF2 | LZE2T | Human | Esophagus | ESCC | 5.27e-03 | 2.48e-01 | 0.082 |
| 10138 | YAF2 | LZE4T | Human | Esophagus | ESCC | 1.30e-10 | 1.95e-01 | 0.0811 |
| 10138 | YAF2 | LZE8T | Human | Esophagus | ESCC | 4.54e-02 | 1.10e-02 | 0.067 |
| 10138 | YAF2 | LZE20T | Human | Esophagus | ESCC | 1.97e-02 | -1.41e-02 | 0.0662 |
| 10138 | YAF2 | LZE24T | Human | Esophagus | ESCC | 1.96e-12 | 2.06e-01 | 0.0596 |
| 10138 | YAF2 | LZE21T | Human | Esophagus | ESCC | 1.29e-03 | 8.65e-02 | 0.0655 |
| 10138 | YAF2 | LZE6T | Human | Esophagus | ESCC | 2.47e-02 | 3.67e-02 | 0.0845 |
| 10138 | YAF2 | P1T-E | Human | Esophagus | ESCC | 4.50e-04 | 2.48e-01 | 0.0875 |
| 10138 | YAF2 | P2T-E | Human | Esophagus | ESCC | 9.38e-25 | 5.11e-01 | 0.1177 |
| 10138 | YAF2 | P4T-E | Human | Esophagus | ESCC | 1.08e-10 | 3.19e-01 | 0.1323 |
| 10138 | YAF2 | P5T-E | Human | Esophagus | ESCC | 1.27e-10 | 6.98e-02 | 0.1327 |
| 10138 | YAF2 | P8T-E | Human | Esophagus | ESCC | 2.48e-29 | 5.81e-01 | 0.0889 |
| 10138 | YAF2 | P9T-E | Human | Esophagus | ESCC | 8.33e-10 | 9.82e-02 | 0.1131 |
| 10138 | YAF2 | P10T-E | Human | Esophagus | ESCC | 1.32e-15 | 3.17e-01 | 0.116 |
| 10138 | YAF2 | P11T-E | Human | Esophagus | ESCC | 6.43e-05 | 1.68e-01 | 0.1426 |
| 10138 | YAF2 | P12T-E | Human | Esophagus | ESCC | 2.42e-09 | 2.98e-01 | 0.1122 |
| 10138 | YAF2 | P15T-E | Human | Esophagus | ESCC | 6.05e-07 | 1.69e-01 | 0.1149 |
| 10138 | YAF2 | P16T-E | Human | Esophagus | ESCC | 4.97e-17 | 2.38e-01 | 0.1153 |
| 10138 | YAF2 | P19T-E | Human | Esophagus | ESCC | 6.96e-03 | 2.38e-01 | 0.1662 |
| 10138 | YAF2 | P20T-E | Human | Esophagus | ESCC | 1.66e-09 | 3.46e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| YAF2 | SNV | Missense_Mutation | novel | c.307N>C | p.Lys103Gln | p.K103Q | Q8IY57 | protein_coding | tolerated(0.06) | possibly_damaging(0.804) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| YAF2 | insertion | Nonsense_Mutation | novel | c.513_514insGGGACGAAGAAACATGCTCAGAGAATTTAGGTTG | p.His172GlyfsTer10 | p.H172Gfs*10 | Q8IY57 | protein_coding | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | ||
| YAF2 | SNV | Missense_Mutation | c.423N>C | p.Glu141Asp | p.E141D | Q8IY57 | protein_coding | tolerated(0.16) | possibly_damaging(0.637) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| YAF2 | SNV | Missense_Mutation | novel | c.468G>T | p.Glu156Asp | p.E156D | Q8IY57 | protein_coding | tolerated(0.07) | probably_damaging(0.953) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| YAF2 | insertion | Frame_Shift_Ins | novel | c.331_332insA | p.Ser111LysfsTer2 | p.S111Kfs*2 | Q8IY57 | protein_coding | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| YAF2 | SNV | Missense_Mutation | novel | c.457G>T | p.Asp153Tyr | p.D153Y | Q8IY57 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| YAF2 | SNV | Missense_Mutation | novel | c.547G>C | p.Glu183Gln | p.E183Q | Q8IY57 | protein_coding | tolerated(0.06) | probably_damaging(0.974) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| YAF2 | SNV | Missense_Mutation | c.357N>T | p.Lys119Asn | p.K119N | Q8IY57 | protein_coding | tolerated(0.06) | benign(0.343) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| YAF2 | SNV | Missense_Mutation | novel | c.575C>A | p.Pro192His | p.P192H | Q8IY57 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A2IN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| YAF2 | SNV | Missense_Mutation | c.308A>C | p.Lys103Thr | p.K103T | Q8IY57 | protein_coding | deleterious(0.03) | benign(0.335) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |